NCT03525080
Completed
Not Applicable
Diagnostic Assessment Study, Single Site and Prospective, comparing18F-DOPA PET and Multiparametric RMI in Initial Exploration of Diffuse Glial Tumors
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Brain Neoplasms
- Sponsor
- Center Eugene Marquis
- Enrollment
- 16
- Locations
- 1
- Primary Endpoint
- PET pictures and MRI sequences comparison
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
For patient having a brain tumor, RMI is the standard exam for tumor characterization and determines initial surgery.
The aim of this study is to assess if PET could provide additional information that could have an impact on surgery (indication and planification)
Investigators
Eligibility Criteria
Inclusion Criteria
- •Suspected glial resectable tumor
- •Free and informed consent
- •Affiliated to French social security
Exclusion Criteria
- •Suspected high grade glioma
- •Surgical emergency
- •Pregnant or breastfeeding woman
- •Patient deprived of their liberty or under guardianship
- •Patient not able to follow study medical monitoring for geographical, social or psychological reasons
- •Treated with carbidopa, catechol-O-methyl transferase inhibitor, haloperidol, reserpine within 2 weeks before PET imagery
Outcomes
Primary Outcomes
PET pictures and MRI sequences comparison
Time Frame: Imagings performed up to 29 days after inclusion (before brain surgery)
Comparison of PET pictures and MRI sequences will be done in order to assess concordance between both imagings
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Protocol to Distinguish Tumor Recurrence From Treatment-Related Necrosis in Patients With High Grade GliomasRecurrent High Grade GliomasNCT00942760Dartmouth-Hitchcock Medical Center12
Unknown
Not Applicable
Development and Validation of Advanced MRI Methods for Clinical ApplicationsBrain TumorNCT03264300St. Joseph's Hospital and Medical Center, Phoenix220
Completed
Phase 2
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for GliomasBrain and Central Nervous System TumorsNCT00274755University of California, San Francisco250
Completed
Phase 3
Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain MetastasisBrain NeoplasmsNCT00681551Bayer45
Recruiting
Not Applicable
MRI Contrast Clearance Analysis for Glioma Grading and GenotypingGliomaNCT06018870Daping Hospital and the Research Institute of Surgery of the Third Military Medical University100